RecruitingPhase 4NCT07195032
Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients
Sponsor
Children's Mercy Hospital Kansas City
Enrollment
60 participants
Start Date
Sep 11, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The study is an interventional, non-randomized assessment of safety and efficacy of live Measles, Mumps and Rubella (MMR) vaccine in subjects aged 12-months to 17 years who have undergone heart transplantation. Subjects who provide permission/assent will receive the commercial MMR vaccine according to product indication and labeling.
Eligibility
Min Age: 1 YearMax Age: 17 Years
Inclusion Criteria7
- Received a heart transplant
- At least 1 year after transplant
- At least 1 year after antibody-mediated rejection treatment (intravenous immune globulin, rituximab, bortezomib, plasmapheresis, carfilzomib, eculizumab, daratumumab)
- At least 1 year from anti-thymocyte globulin
- At least 6 months after pulse dose steroid treatment or basiliximab treatment
- No history of MMR vaccination OR History of MMR vaccination but seronegativity for measles at time of inclusion
- Clinically well
Exclusion Criteria2
- History of repeated infections necessitating adjustment in immunosuppression to non-standard regimen, including single agent immunosuppression and modified trough levels.
- History of anaphylactic reaction to MMR vaccination
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGCommercial measles, mumps, and rubella (MMR) vaccine
Participants will receive the commercial MMR vaccine if they are deemed eligible for the study.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07195032